glp 1 qualifications for glp-1 meds This JAMA Internal Medicine patient page covers #GLP1 weight-loss medications, qualifications for glp-1 meds GLP-1

See how GLP-1s are reshaping diabetes & obesity care.

Viking Therapeutics stock more than doubled on Tuesday following the release of trials results suggesting its injectable obesity treatment outperforms industry leaders like Novo Nordisks Wegovy and Eli Lillys Zepbound.

In recent years, new drugs for the treatment of type 2 diabetes (T2D) have been proposed, including glucagon-like peptide 1 (GLP-1) agonists or sodiumglucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors

A major shift is coming to the GLP-1 weight loss drug market in 2026 one that could dramatically change who can access these medications, how theyre taken, and how much they cost.

See why this tasteless, high-fiber supplement is a daily must-have!

The Food and Drug Administration (FDA) on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and Wegovy, is no longer in short supply. | The demand for weight loss drugs is not slowing down, and many organizations voiced concerns there will likely be semaglutide shortages in the future that will impact patients' access to weight loss medications.